Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System

Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of adoptively transferred CAR T cells, antigen-n...

Descripción completa

Detalles Bibliográficos
Autores principales: Avanzi, Mauro P., Yeku, Oladapo, Li, Xinghuo, Wijewarnasuriya, Dinali P., van Leeuwen, Dayenne G., Cheung, Kenneth, Park, Hyebin, Purdon, Terence J., Daniyan, Anthony F., Spitzer, Matthew H., Brentjens, Renier J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986286/
https://www.ncbi.nlm.nih.gov/pubmed/29768210
http://dx.doi.org/10.1016/j.celrep.2018.04.051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986286/
https://www.ncbi.nlm.nih.gov/pubmed/29768210
http://dx.doi.org/10.1016/j.celrep.2018.04.051

Ejemplares similares